H.C. Wainwright raised the firm’s price target on Cytokinetics (CYTK) to $140 from $136 and keeps a Buy rating on the shares post the Q1 report. The company is seeing strong U.S. Myqorzo launch metrics with solid prescriber base and adopters, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK: